COMPANY

Hinge Bio, Inc.

HQ: Redwood City, CA source · hingebio.com ↗

Hinge Bio’s lead program, HB2198, is a bispecific anti-CD19/anti-CD20 GEM-DIMER™ antibody with two Fc domains, both of which are enhanced for potent binding to Fc gamma receptors on immune effector cells. Hinge Bio’s GEM-DIMER™ platform enables modular design, efficient manufacturing, and precise targeting for a variety of target product profiles and has demonstrated encouraging preclinical efficacy and safety across multiple therapeutic programs. From company website Source · Oct 13, 2026

Keywords: antibody gamma receptors preclinical Systemic Lupus Erthematosus Lupus Nephritis Extra-renal Lupus HB2198

Location: Redwood City, CA · source · Oct 12, 2026

Profile checked Oct 10, 2026

$30.0MRaised (2 yrs)2Trials (company is sponsor)

Raises and deals from press releases

Raise Series A · $30M · announced Jan 15, 2025 Company release ↗
Source quote
- Jan 15, 2025 · Company release ↗
  “Hinge Bio Raises $30 Million Series A’”

Raises announced in these releases: $30M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Mar 23, 2026 Trial start 1: A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) source ↗
Mar 19, 2026 Trial start Phase 1: Single Ascending Dose Study of HB2198 in Healthy Participants source ↗
Sep 30, 2025 Partnership Partnership / licensing announced Sep 30, 2025. Source: company's own press page. source ↗
Jan 15, 2025 Raise Private equity round — Series A: $30M (total, as published), announced Jan 15, 2025. Source: company's own press page. source ↗
Jan 15, 2025 Raise Series A · $30M source ↗

Upcoming milestones

Oct 24, 2027 (ESTIMATED) · 1 · A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) · NCT07491900

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $30.0M. Last 2 years.

Jan 15, 2025 Private equity round — Series A: $30M (total, as published), announced Jan 15, 2025. Source: company's own press page. source ↗
Sep 30, 2025 Partnership / licensing announced Sep 30, 2025. Source: company's own press page. source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT07439263	Single Ascending Dose Study of HB2198 in Healthy Participants	Phase 1	Recruiting	Mar 19, 2026	Aug 14, 2026 (estimated)
NCT07491900	A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)	1	Recruiting	Mar 23, 2026	Oct 24, 2027 (estimated)